Mary Caffrey, American Journal of Managed Care

At the American College of Cardiology Scientific Session, a study of prescriptions for PCSK9 inhibitors confirms what doctors say about trying to get their patients access to the cholesterol drug.

Study compares common treatment options to prevent recurrent venous thromboembolism.

Evolocumab offers a 25% reduction in cardiovascular (CV) death, heart attack, or stroke after the first year.